v
v
HbA1c Levels Are Significantly Lower in Early and Late Pregnancy
v
Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis
v
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
May 1, 2016; 39:686-693
Cardiovascular Disease and Diabetes
v
A Prospective Analysis of the HOMA Model: The Mexico City Diabetes Study
v
Concentrations of Serum Vitamin D and the Metabolic Syndrome Among U.S. Adults
Earl S. Ford
May 1, 2005; 28:1228-1230
BR Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes
v
Improved Glycemic Control in Poorly Controlled Patients with Type 1 Diabetes Using Real-Time Continuous Glucose Monitoring
v
Improvement in Outcomes of Clinical Islet Transplantation: 1999-2010
v
Coronary Heart Disease Incidence and Cardiovascular Mortality in Busselton with Reference to Glucose and Insulin Concentrations
T A Welborn
Mar 1, 1979; 2:154-160
Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications
v
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
v
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
v
Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study
v
Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose
v
Consensus Development Conference on the Diagnosis of Coronary Heart Disease in People With Diabetes: 10-11 February 1998, Miami, Florida
American Diabetes Association
Sep 1, 1998; 21:1551-1559
Consensus Development Conference Report
v
Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes
v
Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
W B Kannel
Mar 1, 1979; 2:120-126
Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications
v
Israeli High Court permits Benjamin Netanyahu to form government despite indictments
A panel of 11 judges ruled that Israeli Prime Minister Benjamin Netanyahu can form a government after reaching a deal with rival Benny Gantz.
v
U.N. triples coronavirus aid appeal to help most vulnerable countries
The United Nations more than tripled its humanitarian aid appeal on Thursday from $2 billion to $6.7 billion to accommodate its updated global plan to help the poorest nations fight the coronavirus pandemic.
v
Ex-South Korea comfort woman accuses activist of exploiting women, funds
A former South Korean comfort woman accused an influential activist group of misappropriating funds and using past victims to advance their cause.
v
Digitizing financial services key to Africa's post-pandemic growth, experts say
As the COVID-19 pandemic begins to take root in Africa, experts say that digitizing financial services could help keep the continent safe
v
South Korea sees new cluster of COVID-19 cases tied to nightclubs
Just days after South Korea loosened its social distancing guidelines, a new COVID-19 cluster of infections has sprung up in the capital city of Seoul tied to several nightclubs.
v
Subdued ceremonies in Europe mark 75th anniversary of VE Day
French President Emanuel Macron led a series of events in Europe Friday that commemorate the 75th anniversary of Victory in Europe Day, with a small ceremony in Paris.
v
Northrop Grumman awarded $123.5M to integrate Navy LAIRCM system
Northrop Grumman received a $123.5 million contract modification Friday to integrate the Department of Navy Large Aircraft Infrared Countermeasures system onto aircraft for the U.S. military and two allied governments.
v
U.S. Navy ships, trailed by Russia, visit Barents Sea above Arctic Circle
U.S. Navy ships on Monday entered the Barents Sea between Norway and Russia, for the first time since the 1980s, "to assert freedom of navigation and demonstrate seamless integration among allies," the U.S. Navy said.
v
Coast Guard names Rear Adm. Melissa Bert as first female judge advocate general
The U.S. Coast Guard named Rear Adm. Melissa Bert as its first female judge advocate and chief counsel, its top legal position.
v
Blue Angels to fly over Dallas, Houston, New Orleans on Wednesday
The U.S. Navy Flight Demonstration Squadron, also known as the Blue Angels, will fly over Dallas/Fort Worth, Houston and New Orleans Wednesday to honor frontline workers fighting the COVID-19 pandemic.
v
Raytheon awarded $325M for repair of ATFLIR system for Navy Super Hornets
Raytheon was awarded a $325 million contract for repair of the Advanced Targeting Forward Looking Infrared System in the F/A-18 Super Hornet aircraft Tuesday, according to the Pentagon.
v
Bell Boeing awarded $10.2M for V-22 Osprey repairs
Bell Boeing received a $10.2 million contract modification Tuesday for repairs of the V-22 Osprey multirole combat aircraft for the Navy, the Pentagon announced.
v
Huntington Ingalls nabs $187.1M for overhaul of USS John C. Stennis
Huntington Ingalls was awarded a $187.1 million contract modification Wednesday for the refueling complex overhaul of USS John C. Stennis, according to the Pentagon.
v
Memo: Prior COVID-19 diagnosis 'permanently disqualifying' for U.S. military service
Military Entrance Processing Stations won't process individuals who have had COVID-19 for military service, even if they've fully recovered from the virus, the Pentagon confirmed this week.
v
Blue Angels to fly over Jacksonville, Miami on Friday
The U.S. Navy Flight Demonstration Squadron, the Blue Angels, will fly over Jacksonville and Miami, Fla., Friday as part of a nationwide tour to show appreciation for healthcare workers and frontline responders.
v
Navy breaks ground on laser weapons test lab in California
Navy leaders and private contractors broke ground this week on what will become the fleet's only dedicated facility to test, fire and evaluate complete laser weapon systems in a maritime environment.
v
Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight
v
Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association
v
Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors
David C. Klonoff
Aug 1, 2018; 41:1681-1688
Emerging Technologies: Data Systems and Devices
v
Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial
Jordi Salas-Salvadó
May 1, 2019; 42:777-788
Continuing Evolution of Nutritional Therapy for Diabetes
v
HbA1c Levels Are Significantly Lower in Early and Late Pregnancy
v
Red and Processed Meats and Health Risks: How Strong Is the Evidence?
v
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
v
Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era
v
Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers
v
Dietary Sugar and Body Weight: Have We Reached a Crisis in the Epidemic of Obesity and Diabetes?: Health Be Damned! Pour on the Sugar
v
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview
v
DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
v
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
v
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum
v
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
v
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
v
Effects of Coffee Consumption on Fasting Blood Glucose and Insulin Concentrations: Randomized controlled trials in healthy volunteers
v
Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People
The long-term influences of sex hormone administration on insulin sensitivity and incretin hormones are controversial. We investigated these effects in 35 transgender men (TM) and 55 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) study.
Before and after 1 year of gender-affirming hormone therapy, body composition and oral glucose tolerance tests (OGTTs) were evaluated.
In TM, body weight (2.8 ± 1.0 kg; P < 0.01), fat-free mass (FFM) (3.1 ± 0.9 kg; P < 0.01), and waist-to-hip ratio (–0.03 ± 0.01; P < 0.01) increased. Fasting insulin (–1.4 ± 0.8 mU/L; P = 0.08) and HOMA of insulin resistance (HOMA-IR) (2.2 ± 0.3 vs. 1.8 ± 0.2; P = 0.06) tended to decrease, whereas fasting glucose (–1.6 ± 1.6 mg/dL), glucose-dependent insulinotropic polypeptide (GIP) (–1.8 ± 1.0 pmol/L), and glucagon-like peptide 1 (GLP-1) (–0.2 ± 1.1 pmol/L) were statistically unchanged. Post-OGTT areas under the curve (AUCs) for GIP (2,068 ± 1,134 vs. 2,645 ± 1,248 [pmol/L] x min; P < 0.01) and GLP-1 (2,352 ± 796 vs. 2,712 ± 1,015 [pmol/L] x min; P < 0.01) increased. In TW, body weight tended to increase (1.4 ± 0.8 kg; P = 0.07) with decreasing FFM (–2.3 ± 0.4 kg; P < 0.01) and waist-to-hip ratio (–0.03 ± 0.01; P < 0.01). Insulin (3.4 ± 0.8 mU/L; P < 0.01) and HOMA-IR (1.7 ± 0.1 vs. 2.4 ± 0.2; P < 0.01) rose, fasting GIP (–1.4 ± 0.8 pmol/L; P < 0.01) and AUC GIP dropped (2,524 ± 178 vs. 1,911 ± 162 [pmol/L] x min; P < 0.01), but fasting glucose (–0.3 ± 1.4 mg/dL), GLP-1 (1.3 ± 0.8 pmol/L), and AUC GLP-1 (2,956 ± 180 vs. 2,864 ± 93 [pmol/L] x min) remained unchanged.
In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization.